PF-06447475

CAS No. 1527473-33-1

PF-06447475( PF06447475 )

Catalog No. M12138 CAS No. 1527473-33-1

PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 39 In Stock
10MG 55 In Stock
25MG 80 In Stock
50MG 120 In Stock
100MG 203 In Stock
200MG 357 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PF-06447475
  • Note
    Research use only, not for human use.
  • Brief Description
    PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively.
  • Description
    PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 of 3 and 11nM for WT LRRK2 and G2019S mutant, respectively; PF-06447475 is also sufficiently potent in the LRRK2 whole cell assay with IC50 of 25 nM; protects nerve-like differentiated cells (NLCs) against rotenone induced noxious effect, prevents α-synuclein-induced neurodegeneration in rats.
  • In Vitro
    PF-06447475 inhibits LRRK2 enzyme and LRRK2 in the whole cell assay with IC50s of 3 and 25 nM, respectively. Cells incubated with PF-06447475 alone (0.5, 1, 3 μM) or in the presence of ROT significantly reduces (S935)-LRRK2 kinase phosphorylation to control. PF-06447475 significantly preserves the nucleus morphology and ΔΨm of NLCs exposed to ROT compared to untreated and control. PF-475 significantly diminishes ROT-induced ROS generation to a similar extent to cells exposed to PF-475 alone.
  • In Vivo
    In G2019S+ rats treated with PF-06447475, a significant reduction in microgliosis to levels found in wild-type rats could be observed. The proinflammatory marker MHC-II expressed on myeloid cells but not neurons also appears to be less abundant in confocal sections in G2019S+ rats treated with PF-06447475. PF-06447475 treatment in G2019S+ rats significantly lowers the number of CD68 cells recruited to the SNpc. PF-06447475 successfully blocks the enhanced neuroinflammation associated with G2019S-LRRK2 expression. Treatment of G2019S+ rats with PF-06447475 preserves TH expression in the dorsal striatum, consistent with drug attenuating neurodegeneration in the SNpc. PF-06447475 is well tolerated in rats.
  • Synonyms
    PF06447475
  • Pathway
    Autophagy
  • Target
    LRRK2
  • Recptor
    G2019SLRRK2|LRRK2
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    1527473-33-1
  • Formula Weight
    305.3339
  • Molecular Formula
    C17H15N5O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 33 mg/mL
  • SMILES
    N#CC1=CC=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=C1
  • Chemical Name
    Benzonitrile, 3-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Henderson JL, et al. J Med Chem. 2015 Jan 8;58(1):419-32. 2. Daher JP, et al. J Biol Chem. 2015 Aug 7;290(32):19433-44. 3. Mendivil-Perez M, et al. Neurochem Res. 2016 Oct;41(10):2675-2692. 4. Volpicelli-Daley LA, et al. J Neurosci. 2016 Jul 13;36(28):7415-27.
molnova catalog
related products
  • GSK2578215A

    GSK2578215A is a highly potent, selective, BBB-permeable LRRK2 inhibitor with IC50 of 10.9 and 9.9 nM for wild-type LRRK2 and the G2019S mutant, respectively.

  • CZC-25146 hydrochlor...

    CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

  • CZC-54252 hydrochlor...

    CZC-54252 hydrochloride is a selective inhibitor of LRRK2 with IC50s of 1.85 nM and 1.28 nM for wild-type and G2019S LRRK2.